Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib in Advanced/Metastatic Sarcoma
NCT01653028Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2012
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alisertib in Liposarcoma, leiomyosarcoma (LMS), undifferentiated sarcoma and 2 more, sponsored by National Cancer Institute. Primary endpoint: Overall Response Rate at 18 months. Started Aug 2012; status: completed.
02
Drugs
alisertib
03
Conditions
Liposarcomaleiomyosarcoma (LMS)undifferentiated sarcomamalignant peripheral nerve sheath tumor (MPNST)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT01653028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01653028.